scholarly journals Determinants of precocious B-cell aging in European adolescences living with perinatally acquired HIV-1 after over 10 years of suppressive therapy

2021 ◽  
Author(s):  
Alessandra Ruggiero ◽  
Giuseppe Rubens Pascucci ◽  
Nicola Cotugno ◽  
Sara Domínguez-Rodríguez ◽  
Rinaldi Stefano ◽  
...  

HIV infection results in a state of chronic immune activation leading to premature immune aging, B-cells dysfunction, that persists despite prolonged virological suppression. In this scenario, adolescence living with perinatally acquired HIV (PHIV), deserve a peculiar attention since potentially exposed for their entire life to chronic immune activation. Here we identified determinants of precocious aging B cells in 40 PHIV undergoing suppressive antiretroviral therapy (ART) for median 13.5 years. All individuals started ART by 2 nd year of life and achieved virus suppression within the 1 st year of ART, with majority of patient maintaining suppression until analysis and 5/40 experiencing viral Spike (transient elevation of HIV-1 VL, 50-999 copies/ml). We employed a multi-omics approach including deep immunological B and T cell phenotype in PBMC, with aging B cells defined by the expression of T-bet and CD11c; plasma proteomics analysis by mass spectrometry and serum level of anti-measles antibodies as correlates of humoral response. We found that individuals with expansion of aging B cell, defined by the expression of T-bet+CD11c+, were those starting treatment later, presenting detectable levels of cell-associated HIV-1 RNA, history of Spikes, and a higher frequency of exhausted T-cells, including those expressing PD-1, LAG3, TIGIT. Accordingly, the proteomic analysis revealed that subjects with expansion of aging B cells and exhausted T cells had enrichment of proteins involved in immune inflammation and complement activation pathways, such as CLU and APCS which are also involved in tumor progression. Signs of precocious aging were associated with a reduced capacity to maintain virological memory against measles vaccination. To our knowledge, this is the first study focusing on precocious B-cell aging and dysfunctionality in PHIV with long-term virological suppression. Our experimental strategy enabled identification of clinical, viral, cellular and plasma soluble markers associated with B-cells aging. Our results pave the way to further define risk of disease progression or lymphoproliferative disorders in PHIV.

2016 ◽  
Vol 213 (11) ◽  
pp. 2413-2435 ◽  
Author(s):  
Yi Wang ◽  
Cindy S. Ma ◽  
Yun Ling ◽  
Aziz Bousfiha ◽  
Yildiz Camcioglu ◽  
...  

Combined immunodeficiency (CID) refers to inborn errors of human T cells that also affect B cells because of the T cell deficit or an additional B cell–intrinsic deficit. In this study, we report six patients from three unrelated families with biallelic loss-of-function mutations in RLTPR, the mouse orthologue of which is essential for CD28 signaling. The patients have cutaneous and pulmonary allergy, as well as a variety of bacterial and fungal infectious diseases, including invasive tuberculosis and mucocutaneous candidiasis. Proportions of circulating regulatory T cells and memory CD4+ T cells are reduced. Their CD4+ T cells do not respond to CD28 stimulation. Their CD4+ T cells exhibit a "Th2" cell bias ex vivo and when cultured in vitro, contrasting with the paucity of "Th1," "Th17," and T follicular helper cells. The patients also display few memory B cells and poor antibody responses. This B cell phenotype does not result solely from the T cell deficiency, as the patients’ B cells fail to activate NF-κB upon B cell receptor (BCR) stimulation. Human RLTPR deficiency is a CID affecting at least the CD28-responsive pathway in T cells and the BCR-responsive pathway in B cells.


2021 ◽  
Author(s):  
Alessandra Ruggiero ◽  
Giuseppe Rubens Pascucci ◽  
Nicola Cotugno ◽  
Sara Domínguez-Rodríguez ◽  
Stefano Rinaldi ◽  
...  

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A572-A572
Author(s):  
Ayana Ruffin ◽  
Anthony Cillo ◽  
Tracy Tabib ◽  
Angen Liu ◽  
Sayali Onkar ◽  
...  

BackgroundCurrent FDA-approved immunotherapies aim to reinvigorate CD8+ T cells, but the contribution of the humoral arm of the immune response in human cancer remains poorly understood. B cells within tissues can mediate anti-tumor immunity and regulate immune responses by presenting antigen and producing tumor-specific antibodies and immunomodulatory cytokines. Head and neck squamous cell carcinoma (HNSCC) can be induced by human papillomavirus (HPV+) and carcinogens such as tobacco and alcohol (HPV-), and the immune infiltrate is quite distinct in the two etiologies, in particular, increased B cells in HPV+ HNSCC patients. Further, increased B cells in HNSCC patients correlate with improved patient survival. Our study seeks to differentiate B cell phenotype, function and location in HPV+ and HPV- HNSCC to identify putative B cell-centric immunotherapeutic targets.MethodsWe utilized a multi-level approach to clearly categorize B cells in HNSCC patients. Single cell RNA sequencing (scRNAseq) was performed on CD45+ tumor infiltrating lymphocytes (TIL) from HPV+ and HPV- HNSCC patients. HNSCC TIL and PBL were stained via spectral cytometry (Cytek Aurora,25 parameters) for unbiased analysis of B cell subsets via computational spectral unmixing. Paraffin embedded slides from HNSCC primary tumors were utilized for multispectral immunofluorescence (mIF) to identify tertiary lymphoid structures (TLS) and identify differences in HPV+ and HPV- disease.ResultsWe demonstrated distinct trajectories for B cells in HPV+ and HPV- disease. HPV- HNSCC tumors mainly contained memory B cells and plasma cells, while the B cells in HPV+ HNSCC were naïve and germinal center (GC). Further, we quantified B cells and CD4+ T cells in TLS, and germinal center-like TLS were associated with improved outcome in HPV+ disease. We also observed that transcriptional and protein expression of Semaphorin A (SEMA4a) was restricted to GC B cells and increased on GC B cells in HNSCC patients compared to healthy tonsils. Additionally, we identified distinct waves of gene expression in GC B cells in HNSCC tumors, ultimately revealing a novel transitional state for GC B cells in the tumor microenvironment (TME).ConclusionsUnderstanding B cell function in human cancers and how different TMEs influence B cells and TLS are important for devising novel therapeutic options for cancer patients. Ultimately, development of therapeutics to enhance B cell responses in the TME should be prioritized as a compliment to T-cell mediated therapies.


2009 ◽  
Vol 83 (21) ◽  
pp. 11407-11411 ◽  
Author(s):  
Veronica D. Gonzalez ◽  
Karolin Falconer ◽  
Kim G. Blom ◽  
Olle Reichard ◽  
Birgitte Mørn ◽  
...  

ABSTRACT Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.


1993 ◽  
Vol 177 (4) ◽  
pp. 925-935 ◽  
Author(s):  
E A Ranheim ◽  
T J Kipps

Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell proliferation and immunoglobulin secretion in a major histocompatibility complex-unrestricted and contact-dependent manner. We find that such activated human CD4+ T cells, but not control Ig-treated T cells, may induce normal or leukemic B cells to express B7/BB1 and significantly higher levels of CD54 intercellular adhesion molecule 1 via a process that also requires direct cell-cell contact. To discern what cell surface molecule(s) may be responsible for signalling B cells to express B7/BB1, we added various monoclonal antibodies (mAbs) specific for T or B cell accessory molecules or control mAbs to cocultures of alpha-CD3-activated T cells and resting B cells. We find that only alpha-CD40 mAbs can significantly inhibit the increased expression of B7/BB1, suggesting that the ligand for CD40 expressed on activated T cells may be an important inducer of B7/BB1 expression. Subsequent experiments in fact demonstrate that alpha-CD40 mAbs, but not control mAbs, induce changes in B cell phenotype similar to those induced by activated T cells when the mAbs are presented on Fc gamma RII (CDw32)-expressing L cells. These phenotypic changes have significant effects on B cell function. Whereas chronic lymphocytic leukemia (CLL) B cells normally are very poor stimulators in allogeneic mixed lymphocyte reactions (MLRs), CLL-B cells preactivated via CD40 crosslinking are significantly better presenters of alloantigen, affecting up to 30-fold-greater stimulation of T cell proliferation than that induced by control treated or nontreated CLL-B cells. Similarly, the MLR of T cells stimulated by allogeneic nonleukemic B cells can be enhanced significantly if the stimulator B cells are preactivated via CD40 crosslinking. The enhanced MLR generated by such preactivated B cells may be inhibited by blocking B7/BB1-CD28 interaction with CTLA4Ig. These studies demonstrate a novel, CD40-dependent pathway for inducing B cell expression of B7/BB1 and enhancing B cell antigen-presenting cell activity that can be initiated via cell-cell contact with alpha-CD3-stimulated CD4+ T cells.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 325-325
Author(s):  
Andrea Cerutti ◽  
Bing He ◽  
April Chiu ◽  
Daniel M. Knowles ◽  
Amy Chadburn ◽  
...  

Abstract Background. Class switch DNA recombination (CSR) from IgM to IgG and IgA is central to immunity against pathogens and requires the activation of B cells by CD4+ T cells through CD40 ligand (CD40L) and cytokines, including IL-4 and IL-10. Viruses evade protective IgG and IgA responses through a number of strategies, including production of soluble proteins that suppress T cell-dependent (TD) class switching in bystander B cells. HIV-1 is thought to impair antigen-specific IgG and IgA production by inducing progressive depletion of CD4+ T cells. Although important, this mechanism is not sufficient to explain the intrinsically poor response of B cells from viremic patients to CD4+ T cell help. This prompted us to explore the B cell-modulating activity of negative factor (Nef), an early HIV-1 protein implicated in immunosuppression. Nef is released in the extracellular environment by infected cells and might perturb the function of bystander B cells by targeting them through its N-terminal myristoylated domain. Methods. Tonsillar tissue sections from healthy donors and lymph nodal tissue sections from 10 HIV-1-infected patients were analyzed for IgD, p24, and Nef expression by immunohistochemistry. Nef expression was also analyzed in IgD+ B cells purified from healthy donors and exposed to a recombinant myristoylated or non-myristoylated Nef protein. These IgD+ B cells as well as an IgD+ B cell line expressing a wild-type Nef transgene or a mutant Nef transgene lacking the myristoylated domain were utilized in CSR assays after further exposure to CD40L, IL-4 and IL-10. CSR and signaling were studied as described1,2,3. Results. We found that HIV-1-infected lymphoid follicles express large amounts of Nef. This viral protein penetrates in bystander B cells both in vivo and in vitro and interferes with the initiation of CSR by CD40L and cytokines without down-regulating CD40 and cytokine receptor expression on B cells. Rather, Nef up-regulates inhibitor of NF-κ B (Iκ B) and suppressor of cytokine signaling (SOCS) proteins, including SOCS1 and SOCS3, in B cells. These powerful inhibitory proteins attenuate the transcriptional activation of germline Ig gene promoters by blocking CD40 and cytokine receptor signaling through NF-κ B and signal transducer and activator of transcription (STAT), respectively. In addition, Nef hampers the up-regulation of key components of the CSR machinery, such as activation-induced cytidine deaminase (AID), and blocks the induction of IgG, IgA and IgE secretion by CD40L and cytokines. Under similar conditions, Nef spares B cell survival, B cell proliferation as well as B cell signaling through mitogen-activated protein kinase p38 and B cell-specific activation protein (BSAP or Pax5). Conclusions. Our findings suggest that HIV-1 inhibits IgG and IgA production not only by impairing CD4+ T cells, but also by turning on powerful CSR inhibitory pathways in bystander B cells through Nef. We propose that Nef-blocking agents might improve protective antibody responses to pathogens and vaccines in HIV-1-infected patients.


2002 ◽  
Vol 76 (17) ◽  
pp. 8855-8863 ◽  
Author(s):  
Angela Malaspina ◽  
Susan Moir ◽  
David C. Nickle ◽  
Eileen T. Donoghue ◽  
Kisani M. Ogwaro ◽  
...  

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) virions bind to B cells in the peripheral blood and lymph nodes through interactions between CD21 on B cells and complement-complexed virions. B-cell-bound virions have been shown to be highly infectious, suggesting a unique mode of HIV-1 dissemination by B cells circulating between peripheral blood and lymphoid tissues. In order to investigate the relationship between B-cell-bound HIV-1 and viruses found in CD4+ T cells and in plasma, we examined the genetic relationships of HIV-1 found in the blood and lymph nodes of chronically infected patients with heteroduplex mobility and tracking assays and DNA sequence analysis. In samples from 13 of 15 patients examined, HIV-1 variants in peripheral blood-derived B cells were closely related to virus in CD4+ T cells and more divergent from virus in plasma. In samples from five chronically viremic patients for whom analyses were extended to include lymph node-derived HIV-1 isolates, B-cell-associated HIV-1 and CD4+-T-cell-associated HIV-1 in the lymph nodes were equivalent in their divergence from virus in peripheral blood-derived B cells and generally more distantly related to virus in peripheral blood-derived CD4+ T cells. These results indicates virologic cross talk between B cells and CD4+ T cells within the microenvironment of lymphoid tissues and, to a lesser extent, between cells in lymph nodes and the peripheral blood. These findings also indicate that most of the virus in plasma originates from cells other than CD4+ T cells in the peripheral blood and lymph nodes.


Sign in / Sign up

Export Citation Format

Share Document